Vera Vlahović-Palčevski

Prof. Dr. Vera Vlahović-Palčevski

1. Department of Clinical Pharmacology, Clinical Hospital center Rijeka, 51000 Rijeka, Croatia
+2

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2013 in BMC Medicine
Verified
Journal Article
Open access
PDF file
BGBrian Godman
Brian Godman
AFAlexander E Finlayson
Alexander E Finlayson
PCParneet K Cheema
Parneet K Cheema
EZEva Zebedin-Brandl
Eva Zebedin-Brandl
IGIñaki Gutiérrez-Ibarluzea
Iñaki Gutiérrez-Ibarluzea
LGLars L Gustafsson
Lars L Gustafsson
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

1 January 2013 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
RMRickard Malmstrom
Rickard Malmstrom
BGBrian Godman
Brian Godman
EDEduard Diogene
Eduard Diogene
CBChristoph Baumgärtel
Christoph Baumgärtel
MBMarion Bennie Marion Bennie
Marion Bennie Marion Bennie
LGLars L. Gustafsson
Lars L. Gustafsson
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have shown dabigatran to be cost-effective but there are budget concerns given the prevalence of AF. There are also issues with potentially re-designing anticoagulant services. This has resulted in activities across countries to better manage its use. Objective: To (i) review authority activities in over 30 countries and regions, (ii) use the findings to develop new models to better manage the entry of new drugs, and (iii) review the implications for all major stakeholder groups. Methodology: Descriptive review and appraisal of activities regarding dabigatran and the development of guidance for groups through an iterative process. Results: There has been a plethora of activities among authorities to manage the prescribing of dabigatran including extensive pre-launch activities, risk sharing arrangements, prescribing restrictions, and monitoring of prescribing post-launch. Reimbursement has been denied in some countries due to concerns with its budget impact and/or excessive bleeding. Development of a new model and future guidance is proposed to better manage the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities. Conclusion: Models for introducing new drugs are essential to optimize their prescribing especially where there are concerns. Without such models, new drugs may be withdrawn prematurely and/or struggle for funding.

20 June 2011 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
Lars BjerrumLars Bjerrum
Lars Bjerrum
AMAnders Munck
Anders Munck
BGBente Gahrn-Hansen
Bente Gahrn-Hansen
MHMalene Plejdrup Hansen
Malene Plejdrup Hansen
DJDorte Ejg Jarbøl
Dorte Ejg Jarbøl
MRMarit Rønning
Marit Rønning
Excessive use of antibiotics is worldwide the most important reason for development of antimicrobial resistance. As antibiotic resistance may spread across borders, high prevalence countries may serve as a source of bacterial resistance for countries with a low prevalence. Therefore, bacterial resistance is an important issue with a potential serious impact on all countries. Initiatives have been taken to improve the quality of antibiotic prescribing in primary care, but only few studies have been designed to determine the effectiveness of multifaceted strategies across countries with different practice setting. The aim of this study was to evaluate the impact of a multifaceted intervention targeting general practitioners (GPs) and patients in six countries with different health organization and different prevalence of antibiotic resistance.

23 April 2010 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
Lars BjerrumLars Bjerrum
Lars Bjerrum
AMAnders Munck
Anders Munck
BGBente Gahrn-Hansen
Bente Gahrn-Hansen
MHMalene Plejdrup Hansen
Malene Plejdrup Hansen
DJDorte Ejg Jarbøl
Dorte Ejg Jarbøl
MRMarit Rønning
Marit Rønning
Excessive and inappropriate use of antibiotics is considered to be the most important reason for development of bacterial resistance to antibiotics. As antibiotic resistance may spread across borders, high prevalence countries may serve as a source of bacterial resistance for countries with a low prevalence. Therefore, bacterial resistance is an important issue with a potential serious impact on all countries.

1 March 2007 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PDF file
VVVera Vlahović-Palčevski
Vera Vlahović-Palčevski
UDUga Dumpis
Uga Dumpis
PMP. Mitt
P. Mitt
JGJ. Gulbinovic̆
J. Gulbinovic̆
JSJ. Struwe
J. Struwe
UBU. Bergman
U. Bergman

27 January 2010 in Pharmacy World & Science
Verified
Journal Article
Closed access
PDF file
VVVera Vlahović-Palčevski
Vera Vlahović-Palčevski
MGMonja Gantumur
Monja Gantumur
NRNives Radošević
Nives Radošević
GPGoran Palčevski
Goran Palčevski
RSRobert Vander Stichele
Robert Vander Stichele